Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease
Key result
Simvastatin 80 mg matches ezetimibe/simvastatin for endothelial improvements, indicating lipid lowering drives the benefit.
- n=39
Why the study?
The importance of the pleiotropic effects of statins on endothelial function and inflammatory markers in patients with dysglycaemia and CAD was not established.
Does simvastatin 80 mg daily improve endothelial function and inflammatory markers compared to ezetimibe 10 mg plus simvastatin 10 mg daily in patients with dysglycaemia and CAD?
Comparison
Simvastatin 80 mg daily vs ezetimibe 10 mg plus simvastatin 10 mg daily
Design
Randomized controlled trial
Follow-up
6 weeks
Authors
Discussion
Loading...
Member takes
Implication
Reinforces LDL reduction as primary driver of endothelial benefits in dysglycaemic CAD; challenges primacy of statin pleiotropic effects.
Key Points
- This study aims to determine whether cholesterol lowering or the pleiotropic effects of statins more significantly affects endothelial function in patients with dysglycaemia and coronary artery disease.
- Patients (N=39) randomized to simvastatin 80 mg daily (S80) or ezetimibe and simvastatin (E10/S10) for 6 weeks.
- Endothelial function measured by brachial artery flow-mediated vasodilatation (FMD) and inflammatory markers assessed at baseline and follow-up.
- Lipid levels and inflammatory markers evaluated, including C-reactive protein.
- Low-density lipoprotein cholesterol decreased significantly in both groups (S80: 3.1 to 1.5 mmol/L; E10/S10: 3.0 to 1.3 mmol/L).
- FMD improved from 4.3% to 5.5% overall, while C-reactive protein declined from 3.1 to 2.3 mg/L but no significant difference between S80 and E10/S10 groups.
Study Design
Type
RCT (n=39)
Structured PICO
Does simvastatin 80 mg daily improve endothelial function and inflammatory markers compared to ezetimibe 10 mg plus simvastatin 10 mg daily in patients with dysglycaemia and CAD?
P
Population
39 patients with dysglycaemia and coronary artery disease randomized to high-dose simvastatin or ezetimibe/simvastatin for 6 weeks.
I
Intervention
Simvastatin 80 mg daily for 6 weeks
C
Comparator
Ezetimibe 10 mg and simvastatin 10 mg daily for 6 weeks
O
Outcome
Endothelial function (evaluated by brachial artery flow-mediated vasodilatation), serum lipids, and inflammatory markers at 6 weekssurrogate
Lipid lowering itself, rather than statin pleiotropic effects, appears to be the primary driver of improvements in endothelial function and inflammatory markers in patients with dysglycaemia and CAD.
Cite This Study
Settergren et al. (2008) conducted an RCT in Dysglycaemia and coronary artery disease (n=39). Simvastatin vs. Ezetimibe 10 mg and simvastatin 10 mg daily was evaluated on Changes in brachial artery flow-mediated vasodilatation (FMD) and C-reactive protein. Simvastatin 80 mg and ezetimibe/simvastatin 10/10 mg produced similar improvements in endothelial function and inflammatory markers, indicating lipid lowering is more important than pleiotropic effects.